Table 1.
Baseline characteristics.
| N=10 | |
|---|---|
| Age, years, median (IQR) | 48.0 (36.75, 58.25) |
| Recipient male, n (%) | 4 (40) |
| Diabetes mellitus, n (%) | 5 (50) |
| Cause of ESRD, n (%) | |
| Diabetes | 5 (50) |
| Hypertension | 1 (10) |
| Chronic GN | 2 (20) |
| Others | 2 (20) |
| Previous CV disease, n (%) | 0 (0) |
| History of smoking, n (%) | 3 (30) |
| BMI, kg/m2, median (IQR) | 22.37 (20.13, 27.93) |
| Dialysis vintage, months, median (IQR) | 3.36 (1.45, 24.53) |
| eGFR, ml/min/1.73 m2, median (IQR) | 5.38 (4.29, 6.75) |
| Donor male, n (%) | 6 (60) |
| Donor age, years, median (IQR) | 41.50 (35.0, 52.75) |
| Systolic BP (mmHg), median (IQR) | 140.0 (120.0, 150.0) |
| Diastolic BP (mmHg) median (IQR) | 80.0 (77.50, 92.50) |
| LV ejection fraction (%), median (IQR) | 62.5 (58.5, 68.3) |
| Rt carotid IMT (mm), median (IQR) | 0.60 (0.55, 0.90) |
| Lt carotid IMT (mm), median (IQR) | 0.65 (0.58, 1.08) |
| Carotid plaque on US, n (%) | 6 (60) |
| TC, mg/dL | 167.0 (146.0, 239.0) |
| Triglyceride, mg/dL | 132.50 (95.25, 220.50) |
| HDL-cholesterol, mg/dL | 36.50 (27.0, 53.50) |
| LDL-cholesterol, mg/dL | 100.0 (88.50, 167.0) |
| HLA mismatch No, median (IQR) | 3.0 (1.75, 4.0) |
| Panel reactive antibody >50%, n (%) | 1 (10) |
| Presence of DSA, n (%) | 0 (0) |
| ABO incompatible, n (%) | 4 (40) |
| Induction therapy | |
| Basiliximab | 10 (100) |
| Anti-thymocyte globulin | 0 (0) |
| Maintenance immunosuppression | |
| Tacrolimus (%) | 10 (100) |
| Mycophenolate mofetil (%) | 10 (100) |
| Desensitization therapy | |
| Rituximab only (%) | 1 (10) |
| Rituximab/Plasmapheresis/IVIG (%) | 4 (40) |
| None | 5 (50) |
IQR – interquartile range; ESRD – end-stage renal disease; BP – blood pressure; CVD – cardiovascular disease; eGFR – estimated glomerular filtration rate; BP – blood pressure; LV – left ventricular; IMT – intima-media thickness; TC – total cholesterol; HDL-C – high-density lipoprotein-cholesterol; LDL-C – low-density lipoprotein-cholesterol; HLA – human leukocyte antigen; IVIG – intravenous immunoglobulin.